Erlotinib in Treating Patients With Advanced Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Kidney Cancer
Interventions
DRUG

OSI-774

OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.

Trial Locations (1)

78229

University of Texas Health Science Center San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT00045487 - Erlotinib in Treating Patients With Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter